Rosuvastatin (Crestor): Complete Clinical Guide to Dosing, Efficacy, and Comparisons

What Is Rosuvastatin and How Does It Work?

Rosuvastatin is a synthetic, fully hydrophilic statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Blocking this enzyme forces hepatocytes to upregulate LDL receptors on their surface, pulling more LDL-cholesterol out of circulation. The net effect is a dose-dependent fall in LDL, a modest rise in HDL, and a reduction in triglycerides. The FDA approved rosuvastatin calcium (Crestor) in August 2003 for adults with primary hypercholesterolemia and mixed dyslipidemia.

Unlike lipophilic statins such as simvastatin or atorvastatin, rosuvastatin does not cross the blood-brain barrier to a significant degree, which may explain its somewhat lower rate of sleep disturbances in observational reports. Its hepatoselectivity also contributes to potent LDL reduction with limited peripheral tissue exposure. A 2002 pharmacokinetic review published in the American Journal of Cardiology confirmed that rosuvastatin achieves higher hepatic concentrations relative to plasma than earlier statins, a property that predicts its superior LDL-lowering per milligram. Bioavailability is approximately 20%, and cytochrome P450 metabolism is minimal, primarily through CYP2C9 with less than 10% of the dose affected, which limits drug-drug interactions compared to atorvastatin or simvastatin.

Dosing begins at 5 to 10 mg daily for most adults. The 20 mg dose is the most commonly prescribed starting point for patients requiring more than a 45% LDL reduction. The maximum approved dose is 40 mg daily. A 2020 Cochrane review of statin dose comparisons (112 trials, N=35,880) confirmed that each doubling of any statin dose produces an additional 6% LDL reduction, so optimizing the baseline molecule matters before titrating upward.

Rosuvastatin Efficacy: Key Trial Data

The JUPITER trial is the landmark evidence base for rosuvastatin in primary prevention. In JUPITER (N=17,802), rosuvastatin 20 mg daily reduced the composite of MI, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death by 44% relative to placebo over a median follow-up of 1.9 years (hazard ratio 0.56 to 95% CI 0.46, 0.69, P<0.00001). The full JUPITER results were published in the New England Journal of Medicine in 2008. LDL fell from a median of 108 mg/dL to 55 mg/dL in the rosuvastatin group, a 50% reduction. HDL rose by 4%.

JUPITER enrolled adults with LDL below 130 mg/dL but elevated high-sensitivity CRP above 2 mg/L, demonstrating that inflammatory risk alone can justify statin therapy even when LDL is not dramatically elevated. This finding shaped the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, which incorporated hsCRP as a risk-enhancing factor in borderline-risk patients.

For secondary prevention, the SATURN trial compared rosuvastatin 40 mg with atorvastatin 80 mg in 1,039 patients with established coronary artery disease. SATURN, published in NEJM in 2011, showed rosuvastatin produced a significantly greater reduction in percent atheroma volume (a surrogate for plaque burden) compared to atorvastatin: mean change of minus 1.22% versus minus 0.99% (P=0.02). Both drugs reduced LDL substantially, but rosuvastatin drove LDL to a median of 62.6 mg/dL versus 70.2 mg/dL with atorvastatin.

Beyond LDL, rosuvastatin reduces triglycerides by 10 to 28% and raises HDL by 8 to 14% depending on baseline values. A 2010 meta-analysis in the Annals of Internal Medicine (N=32,258 across 29 trials) found that rosuvastatin produced larger absolute HDL increases than any other statin at equipotent LDL-lowering doses.

Rosuvastatin vs. Atorvastatin (Lipitor): Head-to-Head

Atorvastatin (Lipitor) is the world's best-selling statin and the most common comparator for rosuvastatin. Both are high-intensity statins per the 2018 ACC/AHA Cholesterol Guideline, which defines high-intensity therapy as producing at least a 50% LDL reduction. Rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg fall in this category.

On a milligram-for-milligram basis, rosuvastatin is roughly twice as potent. Rosuvastatin 10 mg reduces LDL by approximately 46%, while atorvastatin 10 mg reduces LDL by approximately 37%. Rosuvastatin 40 mg achieves roughly 55% LDL reduction; atorvastatin 80 mg achieves about 51 to 54%. A 2009 systematic review in the Journal of the American College of Cardiology comparing 182 statin trials confirmed the potency hierarchy: rosuvastatin ranked highest for LDL reduction per milligram across all dose comparisons.

Atorvastatin has a much longer clinical outcomes database. The ASCOT-LLA trial (N=10,305) showed atorvastatin 10 mg reduced fatal and nonfatal coronary events by 36% compared to placebo over 3.3 years. ASCOT-LLA results are available via The Lancet. CARDS (N=2,838 diabetic patients) showed atorvastatin 10 mg cut major cardiovascular events by 37%. CARDS was also published in The Lancet.

Choosing between the two often comes down to the required LDL target. A patient needing a 50% or greater reduction may reach goal on rosuvastatin 20 mg rather than requiring atorvastatin 80 mg. Lower doses generally mean a smaller absolute myopathy risk, though both drugs carry similar rates at equivalent intensity. Atorvastatin is metabolized extensively via CYP3A4, creating clinically meaningful interactions with drugs like clarithromycin, itraconazole, and certain HIV protease inhibitors. Rosuvastatin's minimal CYP involvement makes it the preferred choice when those interacting agents are co-prescribed.

Rosuvastatin vs. Simvastatin (Zocor): Why Intensity Matters

Simvastatin (Zocor) is a moderate-to-high-intensity statin at doses of 20 to 40 mg, reducing LDL by 35 to 41%. The 80 mg dose was once widely used but is now restricted by FDA due to a documented increase in myopathy and rhabdomyolysis risk. In 2011, the FDA issued a safety communication limiting new initiations of simvastatin 80 mg and requiring a 12-month duration limit before any dose increase to 80 mg is considered.

The PROVE-IT TIMI 22 trial (N=4,162) compared pravastatin 40 mg with atorvastatin 80 mg after acute coronary syndrome and found a 16% relative risk reduction in death or major cardiovascular events favoring high-intensity therapy. PROVE-IT was published in NEJM in 2004. This trial, alongside A-to-Z (N=4,497, simvastatin 40 then 80 mg vs. placebo then simvastatin 20 mg), established that more aggressive LDL lowering reduces events. A-to-Z was published in JAMA in 2004.

For a patient on simvastatin 40 mg with persistent LDL above goal, switching to rosuvastatin 10 to 20 mg typically achieves the needed additional 10 to 20 mg/dL LDL reduction without escalating simvastatin to its restricted 80 mg dose. That is a clinically useful option when a patient cannot tolerate atorvastatin 80 mg.

Rosuvastatin Dosing by Indication and Patient Population

The FDA-labeled dosing is straightforward for most adults but requires adjustment in specific populations. The full FDA prescribing information for rosuvastatin specifies the following:

• Primary hypercholesterolemia and mixed dyslipidemia: Start at 10 to 20 mg once daily; titrate to 40 mg if needed after 4 weeks.
• Homozygous familial hypercholesterolemia: 20 to 40 mg daily, typically in combination with LDL apheresis or PCSK9 inhibition.
• Pediatric patients (ages 8, 17) with heterozygous familial hypercholesterolemia: 5 to 20 mg daily, with doses established by weight and age per FDA labeling.
• Asian patients: The FDA recommends starting at 5 mg due to pharmacokinetic data showing approximately 2-fold higher plasma concentrations in Asian individuals compared to White individuals. This recommendation is supported by a pharmacogenomic analysis published on PubMed.
• Severe renal impairment (eGFR <30 mL/min/1.73m²): Maximum 10 mg daily.
• Concurrent cyclosporine use: Maximum 5 mg daily.
• Concurrent gemfibrozil use: Avoid combination; if unavoidable, maximum 10 mg daily.

Rosuvastatin is taken without regard to food and at any time of day, unlike simvastatin which was traditionally dosed in the evening. Consistent daily timing is recommended to maintain steady-state concentrations. A pharmacodynamic study in Clinical Pharmacokinetics confirmed that morning vs. evening dosing produces equivalent 24-hour LDL-lowering for rosuvastatin due to its long 19-hour half-life.

Side Effects and Safety Profile

Rosuvastatin is well tolerated in the majority of patients. The most common adverse effects reported in clinical trials are headache (5.5%), myalgia (3.6%), and nausea (3.2%). The FDA adverse event summary from the original NDA review places serious adverse event rates below 1% in controlled trials.

Myopathy and rhabdomyolysis. All statins carry a class risk of muscle injury. Myopathy, defined as muscle pain or weakness with CK more than 10 times the upper limit of normal, occurs in fewer than 0.1% of patients on rosuvastatin 40 mg in controlled trials. Rhabdomyolysis is rarer still. The risk rises with higher doses, renal impairment, hypothyroidism, and co-administration of fibrates, niacin, cyclosporine, or certain antiretrovirals. A 2018 systematic review in the BMJ (N=112,000 across 135 trials) found that statin-related myopathy rates across the class were 1 per 10,000 person-years for rhabdomyolysis and 5 per 1,000 person-years for myalgia with normal CK.

New-onset diabetes. Statin therapy as a class increases the risk of new-onset type 2 diabetes by approximately 10 to 12% in relative terms. A 2010 meta-analysis in The Lancet (N=91,140, 13 trials) quantified one additional diabetes case per 255 patients treated with a statin for 4 years. The cardiovascular benefit far exceeds this risk in high-risk populations, but the tradeoff should be discussed with patients who have prediabetes or metabolic syndrome.

Liver enzyme elevations. Persistent elevations of ALT or AST above 3 times the upper limit of normal occur in fewer than 1% of patients. Routine liver function monitoring is no longer recommended by the FDA for asymptomatic patients on stable statin therapy, per the 2012 FDA label change removing mandatory ALT monitoring.

Proteinuria. Dose-dependent dipstick proteinuria has been observed with rosuvastatin, particularly at the 40 mg dose. This appears to represent tubular proteinuria rather than glomerular damage and has not been associated with progressive renal injury in long-term studies.

Adding Ezetimibe (Zetia) to Rosuvastatin

When rosuvastatin at maximum tolerated dose leaves LDL above the patient's target, ezetimibe (Zetia) is the first add-on agent recommended by the 2018 ACC/AHA guideline. Ezetimibe blocks Niemann-Pick C1-Like 1 protein in the intestinal brush border, reducing cholesterol absorption. Added to a statin, it typically lowers LDL by an additional 18 to 24%.

The IMPROVE-IT trial (N=18,144) is the key evidence for this combination. IMPROVE-IT, published in NEJM in 2015, compared simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg alone in patients after acute coronary syndrome. Adding ezetimibe reduced LDL from 69.5 to 53.7 mg/dL and cut the composite cardiovascular endpoint by 6.4% in absolute terms over 7 years (hazard ratio 0.936, P=0.016). The trial established the "lower is better" principle for LDL: every 39 mg/dL reduction in LDL corresponds to a 20 to 25% reduction in major cardiovascular events, regardless of the mechanism used to achieve it, per the Cholesterol Treatment Trialists' Collaboration meta-analysis in The Lancet (N=170,000).

Ezetimibe 10 mg is available as a generic and costs under $15 per month at most pharmacies. The fixed-dose combination tablet Roszet (rosuvastatin/ezetimibe) is FDA-approved and simplifies adherence for patients who need both agents. FDA approval of Roszet is documented in the FDA Orange Book.

Bempedoic Acid (Nexletol) as an Alternative Non-Statin Option

Bempedoic acid (Nexletol) is an oral, non-statin, ATP-citrate lyase inhibitor approved by the FDA in February 2020 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease requiring additional LDL lowering. The FDA approval announcement for bempedoic acid is available on FDA.gov. It reduces LDL by 18 to 22% as monotherapy and by an additional 17 to 18% when added to maximally tolerated statin therapy.

The CLEAR Outcomes trial (N=13,970) tested bempedoic acid 180 mg daily in statin-intolerant patients over a median of 40.6 months. CLEAR Outcomes, published in NEJM in 2023, showed a 13% relative risk reduction in the 4-component MACE endpoint (CV death, nonfatal MI, nonfatal stroke, coronary revascularization) compared to placebo (hazard ratio 0.87 to 95% CI 0.79, 0.96, P=0.004). This is the first outcomes trial for a non-statin oral lipid-lowering drug to demonstrate a statistically significant cardiovascular benefit.

Bempedoic acid does not cause myopathy because it is a prodrug converted to its active form only in the liver, not in skeletal muscle. For patients with documented statin-related myalgia, bempedoic acid offers a mechanistically distinct alternative. A 2021 analysis in the Journal of the American College of Cardiology confirmed that bempedoic acid does not raise CK or worsen muscle symptoms in previously statin-intolerant patients. The fixed-dose combination Nexlizet (bempedoic acid 180 mg / ezetimibe 10 mg) is also FDA-approved and reduces LDL by approximately 36% as add-on to statin therapy.

The key limitation is gout risk: bempedoic acid increases serum uric acid by approximately 0.8 mg/dL and elevated gout incidence from 1.5% to 3.0% in CLEAR Outcomes. Prescribers should assess baseline uric acid levels before initiation.

Statin Intolerance: What It Means and How to Manage It

True statin intolerance, defined as inability to tolerate two or more statins at any dose due to adverse effects, affects an estimated 5 to 10% of statin users based on a 2014 systematic review in the European Heart Journal (27 studies, N=4,197,000). Myalgia without CK elevation is the most common complaint, reported by up to 10% of patients in observational registries but only 1.5 to 3% in placebo-controlled trials, suggesting a significant nocebo effect.

A practical management sequence for suspected statin intolerance:

1. Confirm the symptom is related to the statin by stopping the drug for 2 to 4 weeks and documenting resolution.
2. Re-challenge with the same statin at a lower dose to establish causality.
3. Switch to an alternate statin. Rosuvastatin and fluvastatin have the lowest myalgia rates in comparative observational data, while simvastatin and lovastatin have the highest.
4. Try every-other-day rosuvastatin 5 to 10 mg. A small RCT (N=51) published in the American Journal of Cardiology found every-other-day rosuvastatin 5 mg reduced LDL by 35% in previously intolerant patients with no recurrence of myalgia.
5. Add ezetimibe 10 mg daily if statin tolerance remains limited; the combination of low-dose rosuvastatin plus ezetimibe can match the LDL reduction of full-dose high-intensity monotherapy.
6. Use bempedoic acid 180 mg as a statin-sparing strategy if muscle symptoms persist despite step 4.

The 2022 ACC Expert Consensus Decision Pathway on Statin Intolerance endorses this stepwise approach and explicitly discourages abandoning lipid therapy entirely based on myalgia alone.

Rosuvastatin in Special Populations

Chronic kidney disease (CKD). Rosuvastatin is the preferred statin in moderate CKD (eGFR 30 to 59 mL/min/1.73m²) because it undergoes minimal renal clearance and its hepatic extraction limits systemic accumulation. The SHARP trial (N=9,270 CKD patients) tested simvastatin 20 mg plus ezetimibe 10 mg and showed a 17% relative risk reduction in major atherosclerotic events, providing indirect support for aggressive LDL lowering in CKD. In severe CKD (eGFR <30), cap rosuvastatin at 10 mg daily.

Pregnancy and lactation. Rosuvastatin is contraindicated in pregnancy. Statins inhibit cholesterol synthesis required for fetal development, and animal studies show teratogenicity. Women of childbearing age must use reliable contraception. The drug should be stopped at least 4 weeks before planned conception. The FDA drug labeling places rosuvastatin in the contraindicated category for pregnancy.

Older adults. Adults over 75 with established ASCVD benefit from high-intensity statin therapy, though the absolute benefit per unit of LDL reduction may be smaller than in younger patients. A 2019 meta-analysis in The Lancet (Cholesterol Treatment Trialists, N=14,483 age 75+) showed similar proportional risk reductions per 38.6 mg/dL LDL lowering in older adults as in younger cohorts: 21% reduction per mmol/L LDL reduction (RR 0.79 to 95% CI 0.73, 0.86). Myopathy risk does increase with age, so starting at 5 to 10 mg and titrating is prudent.

Familial hypercholesterolemia (FH). Heterozygous FH affects approximately 1 in 250 people and requires high-intensity statin therapy from diagnosis. The 2021 European Heart Journal guideline on dyslipidemia recommends an LDL target of <100 mg/dL for heterozygous FH patients without ASCVD and <70 mg/dL if ASCVD is present. Rosuvastatin 20 to 40 mg is the first-line statin choice in most FH protocols because of its superior LDL potency. Homozygous FH almost always requires rosuvastatin 40 mg plus ezetimibe and a PCSK9 inhibitor.

Monitoring, Follow-Up, and LDL Targets

Before starting rosuvastatin, obtain a fasting lipid panel, ALT, AST, and CK. Thyroid-stimulating hormone should be checked if hypothyroidism is suspected, as uncontrolled hypothyroidism both elevates LDL and increases myopathy risk. A baseline creatinine helps flag patients who need dose capping.

Recheck the lipid panel at 6 to 12 weeks after initiation or any dose change. Once stable, annual monitoring is sufficient for most patients. CK monitoring is not required in asymptomatic patients. Check CK only if the patient reports new or worsening muscle symptoms.

Per the 2018 ACC/AHA guideline, LDL targets are:

• Very high-risk ASCVD (two or more major ASCVD events, or one major event plus high-risk conditions): below 70 mg/dL, with an option to target below 55 mg/dL based on the 2019 European Society of Cardiology guideline.
• High-risk ASCVD (one major event without additional high-risk conditions): below 70 mg/dL.
• Primary prevention, 10-year ASCVD risk 7.5% or higher: 50% or greater LDL reduction from baseline.
• Primary prevention, risk below 7.5%: Shared decision-making guides whether to treat.

If rosuvastatin 40 mg plus ezetimibe 10 mg leaves LDL above 70 mg/dL in a very-high-risk patient, escalate to a PCSK9 inhibitor (evolocumab or alirocumab). The FOURIER trial (N=27,564) showed evolocumab added to statin therapy reduced major cardiovascular events by 15% over 2.2 years (hazard ratio 0.85, P<0.001) with LDL reduced to a median of 30 mg/dL.